Price
$19.34
Increased by +0.05%
Dollar Volume
1.10 M
ADR%
9.26
Earnings Report Date (estimate)
Nov 8, 22 (-1.15)
Market Cap.
157.89 M
Shares Float
5.64 M
Shares Outstanding
8.16 M
Beta
1.22
Price / Earnings
-8.93
BPR
301.52
20D Range
11.95 20.85
50D Range
10.85 20.85
200D Range
8.39 23.91
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 8, 22 -0.93
Decreased by -520.00%
-1.01
Increased by +7.92%
Mar 2, 22 -0.75
Decreased by -120.59%
-0.25
Decreased by -200.00%
Nov 3, 21 -0.35
Increased by +70.59%
-0.44
Increased by +20.45%
Jul 28, 21 -0.34 -0.37
Increased by +8.11%
Nov 4, 20 -0.15 -0.15
Jul 29, 20 -0.34 -0.15
Decreased by -126.67%
Jun 30, 20 -1.19 -0.54
Decreased by -122.22%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-7.62 M
Decreased by -167.59%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-8.72 M
Decreased by -245.33%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-5.89 M
Decreased by -84.21%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-5.91 M
Decreased by -246.98%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-2.85 M
Decreased by -183.02%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-2.52 M
Decreased by -9.31%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-3.20 M
Decreased by -624.58%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-1.70 M
Decreased by -746.99%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.